Michael Gold, MD
Gynecologic Oncology · Tulsa, OKNPI 1376511956
Payments from drug & device makers
Across 368 payments — averaging $7724.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$965K
- GSK$718K
- Genentech, Inc.$379K
- Tesaro, Inc.$279K
- AstraZeneca$260K
- Clovis Oncology, Inc.$78K
- plus $163K from 19 others
Across 4 payments — averaging $399.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 74 | $965,426 |
| GSK | 57 | $717,893 |
| Genentech, Inc. | 30 | $378,788 |
| Tesaro, Inc. | 16 | $278,599 |
| AstraZeneca | 10 | $260,360 |
| Clovis Oncology, Inc. | 29 | $78,241 |
| AbbVie | 24 | $77,482 |
| Genmab U.S., Inc. | 3 | $32,007 |
| Seagen Inc. | 9 | $28,653 |
| Eli Lilly | 2 | $17,030 |
| Daiichi Sankyo Inc. | 87 | $5,004 |
| Intuitive Surgical | 10 | $1,647 |
| Immunogen, Inc. | 2 | $895 |
| Pfizer | 1 | $200 |
| Regeneron | 1 | $159 |
| Regeneron Healthcare Solutions, Inc. | 1 | $122 |
| Johnson & Johnson | 3 | $51 |
| Novartis | 2 | $38 |
| Conmed Corporation | 1 | $28 |
| Novo Nordisk | 1 | $22 |
| Incyte Corporation | 1 | $21 |
| Bristol Myers Squibb | 1 | $17 |
| Astellas Pharma US Inc | 1 | $16 |
| Millicent US Inc | 1 | $15 |
| Acrotech Biopharma Inc. | 1 | $12 |
How this compares
$2,842,726 in reported general payments places this provider in the 85th percentile of 21 gynecologic oncology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gynecologic oncology in Tulsa
- Katherine MoxleyTulsa$418K
- Daron StreetTulsa$278K
- Alfred JenkinsTulsa$994
- Debra RichardsonOklahoma City$8M
- Robert MannelOklahoma City$5.8M
- Lauren DockeryOklahoma City$3M
- Christina WashingtonOklahoma City$1.6M
- Camille JacksonOklahoma City$886K
- Tara CastellanoOklahoma City$68K
- Joan WalkerOklahoma City$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.